Treatment or prevention of cancer and precancerous disorders

a cancer and precancerous disease technology, applied in the field of cancer or precancerous disease treatment or prevention, can solve the problems of not always possible or desirable surgery, unsuitable treatment for certain skin cancers, and inability to remove skin cancers and actinic keratoses surgically,

Inactive Publication Date: 2010-03-18
CHS PHARMA
View PDF17 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0010]Methods for the treatment of abnormal cells or abnormal cell proliferative diseases such as for example, cancer comprise the administratio

Problems solved by technology

However, these treatments may not be practical for certain skin cancers located on the face and extremities.
Surgical removal of skin cancers and actinic keratoses is not always possible or desirable.
Surgery is not practical when many small actinic keratoses are present, and the scarring produced by surgery is generally unacceptable for exposed, relatively visible areas of the skin.
Furthermore, it is believed that, in the early stages of their development, many skin cancers and actinic keratoses are so small that it would be difficult or impossible to remove surgically because they are not visible to the eye.
Surgery, while necessary for the welfare of the patient, may place the patient at risk and ultimately jeopardize their health if the cancer is located adjacent to certain vital areas, such as the eye.
In addition, surgery may lead to a poor cosmetic effect and l

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Treatment or prevention of cancer and precancerous disorders
  • Treatment or prevention of cancer and precancerous disorders
  • Treatment or prevention of cancer and precancerous disorders

Examples

Experimental program
Comparison scheme
Effect test

example 1

Combination of Sulindac and Sodium Dichloroacetate Selectively Kills Cancer Cells by a Mechanism Involving Reactive Oxygen Species

[0163]Materials and Methods

[0164]Materials: Sulindac, N-acetylcysteine, Tiron were purchased from Sigma (St. Louis, Mo.). DCA sodium salt was obtained from Acros Organics (Geel, Belgium). H2DCFDA and JC-1 were obtained from Molecular Probes (Eugene, Oreg.). MTS assay and Deadend Tunel Kit was obtained from Promega (Madison, Wis.). All cell culture media, fetal bovine serum, and other supplements such as penicillin / streptomycin, glutamine, etc. were purchased from American Type Culture Collection (ATCC; Rockville, Md.).

[0165]Cell Culture: A non small cell lung carcinoma cell line (NSCLC), A549 and a skin carcinoma cell line, SCC25 were purchased from ATCC (Rockville, Md.) and maintained in F12-K medium supplemented with 10% fetal bovine serum, 1× penicillin / streptomycin and 1× glutamine in a humidified, 5% CO2 incubator at 37° C. The normal human lung (MRC...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Epimeraaaaaaaaaa
Login to view more

Abstract

The NSAID, sulindac and/or its metabolites and derivatives, in combination with an agent that generates or induces reactive oxygen species (ROS), significantly enhances the killing of abnormal cells but does not affect normal cells. This effect occurs at concentrations of each compound that individually have little or no activity directed against the abnormal cells.

Description

CROSS REFERENCE TO PRIOR APPLICATIONS[0001]The present application is continuation-in-part (CIP) of application Ser. No. 11 / 925,283 filed Oct. 26, 2007, which is a continuation-in-part (CIP) of application Ser. No. 11 / 388,248 filed Mar. 23, 2006, which claims priority to U.S. provisional application No. 60 / 664,383 filed Mar. 23, 2005, all of which are incorporated herein by reference in their entireties.FIELD OF THE INVENTION[0002]Compositions for treating cancer and methods of treating thereof. In particular, sulindac and / or its metabolites and derivatives, in R- or S-epimeric form with or without an agent that generates reactive oxygen species (ROS), significantly enhances the killing of cancer cells but does not affect normal cells.BACKGROUND OF THE INVENTION[0003]Skin cancer is the most common form of cancer seen in the world. The two most common types of non-melanoma skin cancer include basal cell carcinoma (BCC) and squamous cell carcinoma (SCC). One in five Americans will dev...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/192A61P35/00A61K31/352A61K31/69C12N5/00
CPCA61K31/192A61K31/69A61K31/352A61P35/00
Inventor WEISSBACH, HERBERTRESNICK, LIONELBINNINGER, DAVID
Owner CHS PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap